Press Releases I-Mab

Equities

IMAB

US44975P1030

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
1.5 ^USD	-5.06%		-12.02%	-21.05%

Jun. 06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
Jun. 05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	Jun. 07	AQ
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	Jun. 05	PR
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024	May. 23	AQ
I-Mab to Participate at the Jefferies Global Healthcare Conference	May. 22	PR
I-MAB Filed 2023 Annual Report on Form 20-F	Apr. 30	PR
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 08	AQ
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 05	PR
I-Mab Announces Closing of the Divestiture of Business Operations in China	Apr. 02	PR
I Mab : Resignations of Director and Senior Management - Form 6-K	Apr. 01	PU
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	Feb. 08	AQ
I-Mab Announces Participation at Jefferies and Piper Conferences in November	Nov. 06	PR
I-Mab - Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy	Nov. 03	AQ
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023	Nov. 01	PR
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023	23-10-16	PR
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503	23-10-11	AQ
I Mab : Regains Global Rights to Lemzoparlimab - Form 6-K	23-09-21	PU
I-Mab Announces Upcoming Participation at September Conferences	23-09-05	PR
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates	23-08-18	AQ
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023	23-08-08	PR
TRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab Biopharma	23-07-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases I-Mab

Equities

IMAB

US44975P1030

Press Releases

Filters